Ambys Medicines
Willscott (Scott) Naugler, M.D., graduated from Rhodes College with a B.A. in Creative Writing, then attended the University of Arkansas for Medical Sciences (UAMS). He was a resident in Internal Medicine at Oregon Health & Sciences University (OHSU). Scott then completed a Gastroenterology & Hepatology fellowship at the University of California San Diego, where he also studied liver cancer and inflammation as a post-doctoral fellow in the laboratory of Michael Karin.
Scott joined the faculty at OHSU in 2007 as a transplant hepatologist, while also working for 10 years in the laboratory of Markus Grompe, studying liver regeneration and liver cancer. In 2011 he took on the roles of Medical Director of Liver Transplant and of the Multidisciplinary Liver Tumor Group. Scott serves on the Board of Directors of UNOS, the federal body that manages all solid organ transplants in the U.S., and is passionate about caring for patients with chronic liver disease and liver cancer.
This person is not in the org chart
This person is not in any offices
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.